Vanguard Global Advisers
RPRX icon

Vanguard Global Advisers’s Royalty Pharma RPRX Stock Holding History

Vanguard Global Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Sell
230,477
-8,512
-4% -$443K 0.01% 600
2026
Q1 		$11.5M Buy
+238,989
New +$10.5M 0.01% 599

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's RPRX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Royalty Pharma (RPRX) stake by 3.6% in Q2 2026, selling an estimated $443K and leaving 230,477 shares worth $12.9M. The position accounts for 0.01% of the portfolio, ranked #600.

Vanguard Global Advisers first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 607 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Vanguard Global Advisers held 230,477 shares of Royalty Pharma worth $12.9M as of Q2 2026.
  • Vanguard Global Advisers sold 8,512 Royalty Pharma shares in Q2 2026, an estimated $443K.
  • Royalty Pharma made up 0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #600 holding.
  • Vanguard Global Advisers first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 607 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.